ID   YCMi001-B
AC   CVCL_A9YX
SY   Del-iPSC-Epi6; HA patient iPSC
DR   BioSamples; SAMEA7211857
DR   hPSCreg; YCMi001-B
DR   Wikidata; Q102115138
RX   PubMed=31105049;
RX   PubMed=32798916;
CC   From: Yonsei University College of Medicine; Seoul; South Korea.
CC   Population: Korean.
CC   Sequence variation: Mutation; HGNC; 3546; F8; Unexplicit; Ex8-22del; Zygosity=Hemizygous (PubMed=31105049; PubMed=32798916).
CC   Derived from site: In situ; Adipose tissue; UBERON=UBERON_0001013.
CC   Cell type: Mesenchymal stem cell of adipose tissue; CL=CL_0002570.
DI   NCIt; C27146; Hemophilia A
DI   ORDO; Orphanet_98878; Hemophilia A
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_ZB28 ! YCMi001-A
SX   Male
AG   44Y
CA   Induced pluripotent stem cell
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=31105049; DOI=10.1016/j.stemcr.2019.04.016;
RA   Park C.-Y., Sung J.J., Cho S.-R., Kim J., Kim D.-W.;
RT   "Universal correction of blood coagulation factor VIII in
RT   patient-derived induced pluripotent stem cells using CRISPR/Cas9.";
RL   Stem Cell Reports 12:1242-1249(2019).
//
RX   PubMed=32798916; DOI=10.1016/j.scr.2020.101948;
RA   Sung J.J., Park S., Choi S.-H., Kim J., Cho M.S., Kim D.-W.;
RT   "Generation of a gene edited hemophilia A patient-derived iPSC cell
RT   line, YCMi001-B-1, by targeted insertion of coagulation factor FVIII
RT   using CRISPR/Cas9.";
RL   Stem Cell Res. 48:101948-101948(2020).
//